Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Freenome Scores $160M In New Funding. So What's Next?

Executive Summary

With Freenome recently scoring $160m in new financing, the San Francisco-based start-up is poised to ramp up development of its cancer-detection platform. Medtech Insight hears from the firm's CEO and co-founder, Gabe Otte, about the company's next steps.

You may also be interested in...



Freenome Raises $270M In Series C, Accelerates Trial For Colorectal Cancer Test

Funding will accelerate an FDA registrational study of the company's first liquid biopsy product, as competition increases in early cancer detection.     

Device/Diagnostics Quarterly Dealmaking Statistics, Q3 2019

Device financing increased substantially in Q3, thanks to debt raises led by Insulet. Acquisition dollar volume dropped, though, but Siemens' buy of Corindus for $1.1bn was a stand-out. Diagnostics/research tools financing dropped by 28% from Q2, while acquisition value greatly increased due to Exact Sciences' $2.8bn purchase of Genomic Health.

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT125433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel